Skip to main content

Table 2 Basic information of validation cohort

From: Molecular mechanisms and therapeutic targets of acute exacerbations of chronic obstructive pulmonary disease with Pseudomonas aeruginosa infection

Characteristics

COPD P.A. group

Control group

P

No.

20

10

 

Age, year

67.15 ± 8.99

63.7 ± 5.69

0.280

BMI, kg/m2

22.39 ± 3.33

24.04 ± 1.44

0.147

Smoking

Current smoker

100% (20)

50% (5)

< 0.001

Pack-years

32.50 (25.00, 50.00)

15 (0.00, 36.25)

0.039

Lung Function

FEV1, L

1.48 ± 0.44

2.64 ± 0.75

< 0.001

FVC, L

3.03 ± 0.63

3.52 ± 1.14

0.233

 FEV1/FVC

0.49 ± 0.09

0.76 ± 0.05

< 0.001

GOLD-stage

 I

5% (1)

/

/

 II

65% (13)

/

/

 III

30% (6)

/

/

 IV

0% (0)

/

/

Inflammatory markers

WBC,109/L

9.84 ± 0.93

6.29 ± 0.99

< 0.001

NEU,109/L

7.12 ± 1.12

3.20 ± 0.66

< 0.001

LYM,109/L

1.79 ± 0.51

2.27 ± 0.43

0.015

MONO,109/L

0.49 ± 0.09

0.41 ± 0.15

0.074

EOS,109/L

0.28 ± 0.22

0.19 ± 0.06

0.204

  1. FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; WBC: White blood cell; NEU: Neutrophil; LYM: Lymphocyte; MONO: Monocyte; EOS: Eosinophil